| Weight control and prevention of metabolic syndrome by green tea. | |
| | |
MedLine Citation:
|
PMID: 21193040 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Green tea (Camellia sinensis, Theaceace) is the second most popular beverage in the world and has been extensively studied for its putative disease preventive effects. Green tea is characterized by the presence of a high concentrations of polyphenolic compounds known as catechins, with (-)-epigallocatechin-3-gallate (EGCG) being the most abundant and most well-studied. Metabolic syndrome (MetS) is a complex condition that is defined by the presence of elevated waist circumference, dysglycemia, elevated blood pressure, decrease serum high-density lipoprotein-associated cholesterol, and increased serum triglycerides. Studies in both in vitro and laboratory animal models have examined the preventive effects of green tea and EGCG against the symptoms of MetS. Overall, the results of these studies have been promising and demonstrate that green tea and EGCG have preventive effects in both genetic and dietary models of obesity, insulin resistance, hypertension, and hypercholesterolemia. Various mechanisms have been proposed based on these studies and include: modulation of dietary fat absorption and metabolism, increased glucose utilization, decreased de novo lipogenesis, enhanced vascular responsiveness, and antioxidative effects. In the present review, we discuss the current state of the science with regard to laboratory studies on green tea and MetS. We attempt to critically evaluate the available data and point out areas for future research. Although there is a considerable amount of data available, questions remain in terms of the primary mechanism(s) of action, the dose-response relationships involved, and the best way to translate the results to human intervention studies. |
| | |
Authors:
|
Sudathip Sae-tan; Kimberly A Grove; Joshua D Lambert |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review Date: 2010-12-28 |
Journal Detail:
|
Title: Pharmacological research : the official journal of the Italian Pharmacological Society Volume: 64 ISSN: 1096-1186 ISO Abbreviation: Pharmacol. Res. Publication Date: 2011 Aug |
Date Detail:
|
Created Date: 2011-06-24 Completed Date: 2011-11-09 Revised Date: 2012-05-24 |
Medline Journal Info:
|
Nlm Unique ID: 8907422 Medline TA: Pharmacol Res Country: England |
Other Details:
|
Languages: eng Pagination: 146-54 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Department of Food Science, The Pennsylvania State University, University Park, PA 16802, United States. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Body Weight / drug effects* Catechin / analogs & derivatives*, pharmacology, therapeutic use Flavonoids / pharmacology, therapeutic use Humans Metabolic Syndrome X / prevention & control* Phenols / pharmacology, therapeutic use Polyphenols Tea* |
| Grant Support | |
ID/Acronym/Agency:
|
AT004678/AT/NCCAM NIH HHS; R01 AT004678/AT/NCCAM NIH HHS; R01 AT004678-02/AT/NCCAM NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Flavonoids; 0/Phenols; 0/Polyphenols; 0/Tea; 154-23-4/Catechin; 989-51-5/epigallocatechin gallate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 17?-Hydroxysteroid dehydrogenases (17?-HSDs) as therapeutic targets: Protein structures, functions, ...
Next Document: Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple org...